







THURSDAY 22 SEPTEMBER

8:00 - 9:00	REGISTRATION			8:00 - 9:00
9:15 - 9:40	JOOST BREEKSEMA ICPR 2022 official opening			9:15 - 9:40
9:40 - 10:20	DAVID NICHOLS Overview of psychedelics, from prehistory to the present			9:40 - 10:20
10:20 - 10:30	ROOM CHANGE			10:20 - 10:30
	HUXLEY HALL 	SHULGIN STAGE 	WASSON ROOM 	
	(5-MeO-)DMT for depression	(Lack of) diversity and inclusion in psychedelic research I	Philosophy & phenomenology	
10:30 - 10:55	MICHELLE BAKER JONES & GRAHAM CAMPBELL Exploring the efficacy of DMT assisted therapy as a treatment for depression	ERIKA DYCK Psychedelic margins: reframing history for a more inclusive psychedelic future	JUUSO KÄHÖNEN Psychedelic unselfing and change of values: can self-transcendence in psychedelic experiences clarify values?	10:30 - 10:45
10:55 - 11:20	JOHANNES RECKWEG A phase 1/2 trial of GH001, a vaporized 5-methoxy-N,N-dimethyltryptamine formulation, in patients with treatment resistant depression	HEVAL ÖZGEN Diversity, inclusion and equity in psychedelics science for marginalized populations	MICHAEL KRAMER Toward a phenomenological philosophy of psychedelics	10:45 - 11:00
			GEORGE FEJER A quantitative and qualitative phenomenology of serotonergic and anticholinergic hallucinogens: evidence for multiple pathways to hallucinatory consciousness	11:00 - 11:15
11:20 - 11:50	BREAK			11:20 - 11:50
	Psilocybin for depression	Economics and commercialization of psychedelics	Microdosing I	
11:50 - 12:10	DAVID ERRITZOE Psilocybin vs escitalopram; 6 months follow-up data and effects of expectation	ELLIOT MARSEILLE Agenda for the economic evaluation of psychedelic therapies	KIM KUYPERS Microdosing psychedelics: where are we and where to go from here?	
12:10 - 12:30	MATTHEW WALL Reduced brain responsiveness to emotional stimuli with escitalopram but not psilocybin therapy for depression	LIONEL THELEN Psychedelics at the frontiers of science and... Beyond with the ERC funding opportunities	VINCE POLITO Is microdosing just placebo? Reasons for and against	
12:30 - 12:50	METTEN SOMERS Single-dose psilocybin for a treatment resistant episode of major depression	MICHAEL MULLETTE MDMA-assisted therapy – the road to patient access	BALAZS SZIGETI How to adjust microdosing trial results for the quality of blinding?	
12:50 - 14:20	LUNCH & POSTER PRESENTATIONS			
	Understanding MDMA-assisted therapy	Mapping the psychedelic brain	Psychedelics beyond the individual	
14:20 - 14:40	MATTHEW BAGGOTT What are the neuropharmacological mechanisms of MDMA's magic?	KATE GODFREY Electrophysiological (EEG) markers of human neuroplasticity in psychedelic research	YOGI HENDLIN Deep ecology and ecodelic experience	
14:40 - 15:00	PARKER SINGLETON MDMA-assisted therapy alters neural activity patterns in adults with chronic and severe post-traumatic stress disorder	DRUMMOND MCCULLOCH Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses	MATEO SANCHEZ PETREMENT Resonance: situating experience and bridging the individual and social potentials of psychedelics	




THURSDAY 22 SEPTEMBER

15:00 - 15:10	ROOM CHANGE			15:00 - 15:10
	Mushrooms versus synthetic psilocybin	Mysticism	Therapeutic uses of psilocybin / mushrooms	
15:10 - 15:50	<p>PAUL STAMETS Synthetic psilocybin vs. psilocybin mushrooms: neurogenerative properties</p>	<p>(ONLINE) DANA SAWYER Aldous Huxley's 'minimum working hypothesis' of psychedelically occasioned mystical experience(s) and why it continues to be relevant for psychedelic studies today</p>	<p>WINSTON DE LA HAYE Psychedelics for use and wellbeing; cultural context and recent developments: a Jamaican perspective</p>	15:10 - 15:30
		<p>AIDAN LYON Can science and mysticism be reconciled?</p>	<p>EMMANUELLE SCHINDLER Efficacy and safety of psilocybin in the prevention of headache disorders: results from two preliminary clinical trials</p>	15:30 - 15:50
15:50 - 16:20	BREAK			15:50 - 16:20
	SYMPOSIUM Access, reciprocity and conduct	SYMPOSIUM Psychedelic aesthetics	SYMPOSIUM Psychedelic research in the Netherlands towards a network of excellence	
16:20 - 17:20	<p>ANNE KATRIN SCHLAG How can we ensure reciprocity and sustainability?</p> <p>JULIA BORNEMANN Access, equity, and harm reduction in the future of psychedelic care</p> <p>ASHLEIGH MURPHY-BEINER & ROBERTA MURPHY Building a lighthouse: ethical guidelines for psychedelic therapists in clinical contexts</p>	<p>MARCO AQLI Visual hallucinations: at the edge of nature and culture</p> <p>AMIR VUDKA Drinking the cosmic soup: transcendental style as a plane of immanence in the work of Vincent Moon</p> <p>PATRICIA PISTERS The limits of perception: nonhuman aesthetics and affective intensity</p> <p>SANDER BOS Psychedelic art in a time of digital transformation</p>	<p>Panelists JAN RAMAEKERS TIJMEN BOSTOEN MICHEL VAN ELK ROBERT SCHOEVERS BRIGITTE ADRIAENSEN</p> <p>Moderator JOOST BREEKSEMA</p>	16:20 - 17:20
17:20 - 17:30	ROOM CHANGE			17:20 - 17:30
	PANEL Benefits, risks and challenges of therapist's self-experience	ART PERFORMANCE	PANEL Novel compounds or existing molecules	
17:30 - 18:15	<p>Panelists IVAR GOKSØYR JANIS PHELPS TORSTEN PASSIE ROBERTA MURPHY</p> <p>Moderator TIJMEN BOSTOEN</p>	<p>Petites Planètes - Live Cinema by VINCENT MOON</p>	<p>Panelists DAVID NICHOLS MICHELLE BAKER-JONES PAUL STAMETS JUDY ASHWORTH</p> <p>Moderator MATTHEW BAGGOTT</p>	17:30 - 18:15
18:15 - 19:15	RELAX & CONNECT			18:15 - 19:15




FRIDAY 23 SEPTEMBER

9:00 - 9:30	ARRIVAL			9:00 - 9:30
	HUXLEY HALL 	SHULGIN STAGE 	WASSON ROOM 	
	Psychedelic therapy: Lessons from the past and challenges for the future	(Lack of) diversity and inclusion in psychedelic research II	Dosing DMT	
9:30 - 9:55	TORSTEN PASSIE Lessons from the first wave of psychedelic research and therapy 1960-1975	MONNICA WILLIAMS The inclusion and exploitation of people of color in psychedelic research	EMMA ECKERNÄS Understanding the relationship between DMT exposure and its effects – implications for dose considerations	9:30 - 9:55
9:55 - 10:20	CHARLES RAISON Five questions that will determine the future of psychedelics in mainstream medicine	SONYA FABER The importance of cultural competency and anti-racist education for psychedelic assisted therapy - understanding aversive racism	LISA LUAN Using continuous infusion to extend the DMT experience	9:55 - 10:20
10:20 - 10:30	ROOM CHANGE			10:20 - 10:30
	Palliative care	Neuroscience of psychedelics	Beyond mescaline	
10:30 - 10:55	BILL RICHARDS Psilocybin in palliative care: current status	DAVID NUTT The neuroscience of psychedelics in health and mental illness	CHRISTIAN POULIE Pharmacological evaluation of the 'other' Lophophora alkaloids	10:30 - 10:55
10:55 - 11:20	HOUMAN FARZIN Psychedelic medicines for existential distress associated with life-threatening illnesses	AMANDA FEILDING LSD and the importance of changes in the cerebral blood supply: from expanded states of consciousness to new therapeutic interventions	DINO LUETHI Beyond peyote: the pharmacology of novel psychedelic phenethylamines	10:55 - 11:20
11:20 - 11:50	BREAK			11:20 - 11:50
	Novel results from RCTs on anxiety and alcohol use disorders	Psychedelic pharmacology	Cognition and perception	
11:50 - 12:20	PETER GASSER & FRIEDERIKE HOLZE LSD treatment in persons suffering from anxiety symptoms in severe somatic diseases or in psychiatric anxiety disorders: a randomized, double-blind, placebo-controlled phase II study. History, Results, Outlook	MATTHIAS LIECHTI Dosing psychedelics	ISABEL WIESSNER LSD and the stream of thought: increased discontinuity of mind, deep thoughts and abstract flow	11:50 - 12:10
12:20 - 12:50	MICHAEL BOGENSCHUTZ Effects of psilocybin in the treatment of alcohol use disorder	ANNA BECKER Effects of the 5-HT2A receptor antagonist ketanserin after LSD administration in healthy subjects	STEPHANIE MULLER Effects of psilocybin on complex naturalistic perception and expression	12:10 - 12:30
12:30 - 12:50			NATASHA MASON Spontaneous and deliberate creative cognition during and after psilocybin exposure	12:30 - 12:50
12:50 - 14:20	LUNCH & POSTER PRESENTATIONS			12:50 - 14:20
14:00 - 14:10		INTROSPECTIVE MUSIC JOURNEY KARIMA EL FILLALI SPINOZA MUSIC		14:00 - 14:10
	Challenging dominant discourses on psychedelics	Therapeutic models	Reciprocity	
14:20 - 14:40	DAVID YADEN Addressing psilocybin research hype: an evidence-based approach	JEFF GUSS, JORDAN SLOSHOWER, ROB KRAUSE Psychedelic phenomenology, the ACT hexaflex model and psychedelic therapy	VINCENT VERROUST Psilocybin intellectual property, roots of psychedelic research, indigenous reciprocity: not that simple	14:20 - 14:40
14:40 - 15:00	BRIAN PACE Right-wing psychedelia: red pills for sale	BILL BRENNAN Introducing EMBARK: a trans-diagnostic, trans-drug model of psychedelic-assisted psychotherapy and therapist training	KIRAN AHMAD Ibogaine & reciprocity	14:40 - 15:00
15:00 - 15:10	ROOM CHANGE			15:00 - 15:10

FRIDAY 23 SEPTEMBER

	HUXLEY HALL 	SHULGIN STAGE 	WASSON ROOM 	
	(Re)framing the psychedelic renaissance	Ethics and professional conduct in psychedelic therapy	Deleuze and psychedelics	12:10 - 12:30
15:10 - 15:30	DAAN OOSTVEEN Posthuman psychedelics: how to move beyond health and capital	CAROLINA SEYBERT Ethical challenges of altered states of consciousness in the treatment setting	JOÃO GUILHERME RIBEIRO Into the virtual: a Deleuzian account of psychedelic experience	12:30 - 12:50
15:30 - 15:50	DAVID DUPUIS Can psychedelics really change the world?	ROBERT SCHOEVERS Psychedelic treatments and the risk of boundary violations	JOS TEN BERGE Modernist discourse, or how cultural history influenced drug research	12:50 - 14:20
15:50 - 16:20	BREAK			15:50 - 16:20
	SYMPOSIUM Belief changes and mysticism	PANEL Psychedelic therapy: ethics, risks, and professional boundaries	Therapeutic processes and intentions	14:20 - 14:40
16:20 - 17:20	DAVID YADEN Agnostic frames for metaphysical claims in psychedelic experiences	Panelists MONNICA WILLIAMS PETER GASSER CORINE DE BOER ASHLEIGH MURPHY-BEINER Moderator ROBERT SCHOEVERS	ROBERTA MURPHY The impact of the therapeutic alliance on the acute psychedelic experience and clinical outcomes in depression	14:40 - 15:00
	SAMULI KANGASLAMPI The role of mystical-type experiences in improved well-being after psychedelic use – a comprehensive review of the evidence		JORDAN SLOSHOWER The role of psychological flexibility in psilocybin-assisted therapy of major depression	16:40 - 17:00
	PETER SJÖSTEDT-HUGHES On the need for metaphysics in psychedelic research		MARIA AMATO A qualitative analysis of over 2000 participants' intentions to participate in a psychedelic retreat	17:00 - 17:20
	JOSJAN ZIJLMANS Moving past mysticism in psychedelic science			
	JUSSI JYLKKÄ Naturalism and mysticism in psychedelic science			
17:20 - 17:30	ROOM CHANGE			17:20 - 17:30
	PANEL Mainstreaming psychedelics: democratization and medicalization	PANEL The role of music in psychedelic therapy	PANEL Funding and regulating medical psychedelics in Europe	
17:30 - 18:15	Panelists RICK DOBLIN JULIA MANDE MATTHIAS LIECHTI SHAYLA LOVE Moderator THIJS ROES	MENDEL KAELEN The essential role of music in psychedelic therapy: 10 years of research	Panelists LIONEL THELEN GITTE MOOS KNUDSEN TADEUSZ HAWROT FLORENCE BUTLEN-DUCUING Moderator DAVID NUTT	17:30 - 18:15
18:15 - 19:15	RELAX & CONNECT			18:15 - 19:15

SATURDAY 24 SEPTEMBER

9:00 - 9:30	ARRIVAL			9:00 - 9:30
	HUXLEY HALL 	SHULGIN STAGE 	WASSON ROOM 	
	Critical perspectives on the quality of psychedelic research	Mapping the psychedelic brain	Methylone	
9:30 - 9:55	CHRISTINE HAUSKELLER Problems with clinical trials in psychedelic-assisted therapies	KATRIN PRELLER The effects of psychedelics on the human brain	JENNIFER SCHMIDT Methylone, a rapid acting entactogen with robust antidepressant-like activity in the forced swim test	9:30 - 9:55
9:55 - 10:20	MICHIEL VAN ELK A roadmap for improving psychedelic science	GITTE MOOS KNUDSEN Sustained effects of single doses of classical psychedelics in humans	BEN KELMENDI A case series presenting clinical evidence for the use of methylone in the treatment of PTSD	9:55 - 10:20
10:20 - 10:30	ROOM CHANGE			10:20 - 10:30
	PANEL Psychedelics: science meets business	Clinical trials vs. patient needs	Psychedelic and psychiatric drug interactions	
10:30 - 11:20	Panelists ULF BREMBERG SHERRY RAIS AMIR INAMDAR KIM KUYPERS Moderator SHAYLA LOVE	EDWARD JACOBS When the trial ends: the ethical and pragmatic case for post-trial provisions in clinical psychedelic research	KELAN THOMAS Integrating psychedelic therapy into psychiatry: evaluating the potential risks of combining psychedelics and psychiatric medications in clinical practice	10:30 - 10:55
		LEONIE SCHNEIDER & IAN ROULLIER The importance of the participant voice	JAN THOMANN Drug metabolism and pharmacokinetics of psilocin in vitro and in humans	10:55 - 11:20
11:20 - 11:50	BREAK			11:20 - 11:50
	MDMA-assisted therapy around the world	PANEL Participant perspectives on psychedelic trials	FILM SCREENING Descending the Mountain	
11:50 - 12:10	CORINE DE BOER MDMA-assisted therapy clinical trials in PTSD in Europe: an update	Panelists LEONIE SCHNEIDER IAN ROULLIER PEDRAM DARA Moderator JOOST BREEKSEMA	Followed by Q&A with co-producer ANNETTE BADENHORST	11:50 - 12:50
12:10 - 12:50	RICK DOBLIN MDMA: from therapy drug to party drug back to therapy drug and beyond			
12:50 - 14:20	LUNCH & POSTER PRESENTATIONS			12:50 - 14:20
14:00 - 14:10		INTROSPECTIVE MUSIC JOURNEY JANNEKE KRIJGSMAN SPINOZA MUSIC		14:00 - 14:10
	Psychedelics and the nature of reality	Insights & illusions in psychedelic therapy	Indigenous medicine in/beyond the Amazon	
14:20 - 15:00	BERNARDO KASTRUP Psychedelic effects are one piece of a much bigger puzzle	(ONLINE) RUBEN LAUKKONEN A theory of true and false insight: implications for psychedelic therapy	ANDRÉ VAN DER BRAAK Making sense of ayahuasca religiosity in the West: a Latourian approach	14:20 - 14:40
		CHRISTOPHER TIMMERMANN Psychedelic apprenticeship in clinical practice, traditional contexts, and consciousness science	ILANA BERLOWITZ Indigenous Amazonian therapy using liquid psychoactive tobacco as medicine: results from a multimodal transdisciplinary clinical study	14:40 - 15:00
15:00 - 15:10	ROOM CHANGE			15:00 - 15:10

SATURDAY 24 SEPTEMBER

	HUXLEY HALL 	SHULGIN STAGE 	WASSON ROOM 	
	Psilocybin, consciousness and mysticism	Charting the way forward in psychedelic research	Microdosing II	
15:10 - 15:50	(ONLINE) ROLAND GRIFFITHS Psilocybin-occasioned mystical-type experiences: implications for consciousness, altruism, and spirituality	ROTEM PETRANKER Manifest your desires: psychedelics and the self-help industry	ALEKSI HUPLI Using digital tools to study emerging drug trends: psychedelic microdosing on YouTube	15:10 - 15:30
		TEHSEEN NOORANI Reimagining (psychedelic) drug evaluation processes	MAGGIE KIGARA Personal science to maximize scientific impact: n-of-1 report of the world's largest mobile microdosing study	15:30 - 15:50
15:50 - 16:20	BREAK			15:50 - 16:20
	Lessons for psychedelic therapists	PANEL Blinding, expectancy and hype: reimagining psychedelic trials	Literary, cultural, and linguistic perspectives	
16:20 - 16:50	PETER GASSER Working as a couple in psychedelic therapy. Dreams - Difficulties - Dangers.	Panelists MICHEL VAN ELK ROTEM PETRANKER ERIKA DYCK Moderator TEHSEEN NOORANI	PATRICK EVERITT 'Whenever in doubt, turn off your mind, relax, float downstream': The Psychedelic Experience (1964) - an early manual of entheogenic esotericism	16:20 - 16:40
			JOHANNA SOPANEN Journeying in the unconscious; Jung's Liber Novus and the psychedelic experience	16:40 - 17:00
16:50 - 17:20	JANIS PHELPS Radical commitment to self-reflection and peer review: 10 values and skills of the ethical psychedelic therapist		MARK SCHUNEMANN Entities in lysergic literature - history or mystery	17:00 - 17:20
17:20 - 17:30	ROOM CHANGE			17:20 - 17:30
17:30 - 18:15	CLOSING PANEL			17:30 - 18:15
18:15 - 19:15	RELAX & CONNECT			18:15 - 19:15